# Table 1. Characteristics of included studies – Extended reality

| Study | Participants (number, age, other important characteristics) | Comparison | Follow-up | Outcome measures | Comments | Risk of bias* |
|---|---|---|---|---|---|---|
| Richardson, 2019<br><br>*RCT, USA* | **N at baseline**<br><br>Intervention: 29<br><br>Control: 30<br><br><br>**Age (mean, SD)^:**<br><br>44.8 (10.8) years<br><br><br>**Sex (% female)^:** 20%<br><br><br>**Mean time of lesion (SD)^:**<br><br>14.9 (11.0) years<br><br><br>**Injury level (n, %)**<br><br>Tetraplegia: 25 (42.4)<br><br>Paraplegia: 34 (57.6)<br><br><br>**NP-SCI level (n, %)**<br><br>Intervention: | Intervention:<br><br>Virtual walking<br><br>*20 minutes*<br><br><br>Control:<br><br>Virtual wheeling<br><br>*20 minutes* | Not specified, post-treatment. | Pain | Potential conflicts of interest are not reported.<br><br>The study was supported by the United States Department of Health and Human Services. | High |

| | | | | | | |
|---|---|---|---|---|---|---|
| | At-level: 14 (17.3)<br><br>Below-level: 32 (39.5)<br><br>At-/below-level: 35 (43.2)<br><br>Control:<br><br>At-level: 6 (9.1)<br><br>Below-level: 26 (39.4)<br><br>At-/below-level: 34 (51.5)<br><br>**ASIA**:<br><br>NR | | | | | |
| Soler, 2010<br><br>*RCT, Spain* | **N at baseline**<br><br>Intervention: 10<br><br>Control: 10<br><br>**Age (mean)**:<br><br>Intervention: 48.6 years<br><br>Control: 45.0 years<br><br>**Sex (% female)**<br><br>Intervention: 33%<br><br>Control: 30% | Intervention:<br><br>Visual illusion combined with sham transcranial DCS<br><br>*Ten 20-minute sessions over a period of two weeks*<br><br>Control:<br><br>Control illusion combined with sham transcranial DCS<br><br>*Ten 20-minute sessions over a period of two weeks* | 24 days | Pain | Potential conflicts of interest are not reported.<br><br>The study was supported by research grants (BBVA Translational research Chair in Biomedicine, the International Brain Research Foundation (IBRF) and National Institutes of Health). | Some concerns for both outcome measures. |

Table 1. Characteristics of included studies – Extended reality
Richtlijn Dwarslaesierevalidatie 2025

| | | | | | |
|---|---|---|---|---|---|
| | **Mean time of lesion**: | | | | |
| | Intervention: 10.9 years | | | | |
| | Control: 8.6 years | | | | |
| | | | | | |
| | **Injury level (n, %)** | | | | |
| | Intervention: | | | | |
| | Cervical level: 1 (11.1) | | | | |
| | Thoracic level: 8 (88.9) | | | | |
| | Control: | | | | |
| | Cervical level: 4 (40) | | | | |
| | Thoracic level: 6 (60) | | | | |
| | | | | | |
| | **NP-SCI level (n, %)** | | | | |
| | Intervention: | | | | |
| | At-level: 0 (0) | | | | |
| | Below-level: 6 (66.7) | | | | |
| | At-/below-level: 3 (33.3) | | | | |
| | Control: | | | | |
| | At-level: 0 (0) | | | | |
| | Below-level: 7 (70) | | | | |
| | At-/below-level: 3 (30) | | | | |

Table 1. Characteristics of included studies – Extended reality
Richtlijn Dwarslaesierevalidatie 2025

| | | | | | | |
|---|---|---|---|---|---|---|
| | **ASIA**: <br><br> Intervention: <br><br> A: 7 (77.8) <br><br> B: 2 (22.2) <br><br> C: 0 (0) <br><br> D: 0 (0) <br><br> Control: <br><br> A: 8 (80) <br><br> B: 2 (20) <br><br> C: 0 (0) <br><br> D: 0 (0) | | | | | |
| Trost, 2022 <br><br> *CCT, USA* | **N at baseline** <br><br> Intervention: 17 <br><br> Control: 10 <br><br><br> **Age (mean, SD)^**: <br><br> 42.5 (12.4) years <br><br><br> **Sex (% female)** <br><br> Intervention: 6% <br><br> Control: 40% | Intervention: <br><br> Interactive VRWalk intervention <br><br> *Ten daily sessions within a 2-week timeframe* <br><br><br> Control: <br><br> Passive, noninteractive virtual walking condition <br><br> *Ten daily sessions within a 2-week timeframe* | 2 weeks | Pain | The authors declare no conflicts of interest. <br><br> The study received no financial/funding support. | Some concerns for both outcome measures. |

Table 1. Characteristics of included studies – Extended reality
Richtlijn Dwarslaesierevalidatie 2025

| | | | | | |
|---|---|---|---|---|---|
| | **Mean time of lesion**:<br><br>Intervention: 13.7 years<br><br>Control: 7.0 years<br><br><br>**Injury level (n, %)**<br><br>Intervention:<br><br>Cervical level: 1 (5.8)<br><br>Thoracic level: 16 (94.1)<br><br>Control:<br><br>Cervical level: 0 (0)<br><br>Thoracic level: 10 (100)<br><br><br>**NP-SCI level (n, %)**<br><br>Intervention:<br><br>At-level: 0 (0)<br><br>Below-level: 16 (94.1)<br><br>At-/below-level: 0 (0)<br><br>Above-/below-level: 1 (5.8)<br><br>Control:<br><br>At-level: 0 (0)<br><br>Below-level: 7 (70) | | | | |

Table 1. Characteristics of included studies – Extended reality
Richtlijn Dwarslaesierevalidatie 2025

| | | | | | | |
|---|---|---|---|---|---|---|
| At-/below-level: 2 (20)<br><br>Above-/below-level: 1 (10)<br><br><br>**ASIA**:<br><br>Intervention:<br><br>A: 17 (100)<br><br>B: 0 (0)<br><br>C: 0 (0)<br><br>D: 0 (0)<br><br>Control:<br><br>A: 10 (100)<br><br>B: 0 (0)<br><br>C: 0 (0)<br><br>D: 0 (0) | | | | | | |

*Abbreviations: ASIA = American Spinal Injury Association impairment scale; CCT = controlled clinical trial; DCS = direct current stimulation; NP = neuropathic pain; NRS = numeric rating scale; RCT = randomized controlled trial; SCI = spinal cord injury; SD = standard deviation; VR = virtual reality.*

*\*Risk of bias is presented per outcome measure (if necessary). For further details, see risk of bias table in the appendix*

*^Values were reported for the total study population only*

Table 1. Characteristics of included studies – Extended reality
Richtlijn Dwarslaesierevalidatie 2025